Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

BACKGROUND: An intranasal formulation of esketamine, combined with an oral antidepressant, is approved in the USA and the European Union for adults with treatment-resistant depression (TRD). Transient cardiovascular stimulatory effects have been reported with ketamine. METHODS: Cardiovascular effect...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:CNS Drugs
Prif Awduron: Doherty, Teodora, Wajs, Ewa, Melkote, Rama, Miller, Janice, Singh, Jaskaran B., Weber, Michael A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer International Publishing 2020
Pynciau:
Original Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048867/
https://ncbi.nlm.nih.gov/pubmed/31994024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-020-00699-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg